Early detection and quantification of mutations in the tyrosine kinase domain of chimerical BCR-ABL1 gene combining high-resolution melting analysis and mutant-allele specific quantitative polymerase chain reaction

Leukemia and Lymphoma

Volumn 54, Issue 3, 2013, Pages 598-606

  Ferri, Cristian ^a   Bianchini, Michele ^a   Icardi, Gustavo ^a   Belli, Carolina ^a   Bengió, Raquel ^b   Larripa, Irene ^a,b  

^a ACADEMIA NACIONAL DE MEDICINA   (Argentina)

^b INST DE INVEST HEMATOLOGICAS   (Argentina)

Author keywords

ARMS; CML; HRM; Mutations; Screening

Indexed keywords

BCR ABL PROTEIN; DASATINIB; IMATINIB; NILOTINIB; PLASMID DNA;

ADULT; AGED; ARTICLE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG TREATMENT FAILURE; EARLY DIAGNOSIS; FEMALE; GENE MUTATION; GENETIC VARIABILITY; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; HUMAN TISSUE; MALE; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR VOLUME;

ADULT; AGED; ALLELES; DNA MUTATIONAL ANALYSIS; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTEIN-TYROSINE KINASES; REPRODUCIBILITY OF RESULTS; TRANSITION TEMPERATURE; YOUNG ADULT;

EID: 84873326170     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.718767     Document Type: Article

References (27)

1. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355: 2408-2417.
2. Branford S, Melo JV, Hughes TP. Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? Blood 2009;114: 5426-5435.
3. Khorashad JS, Anand M, Marin D, et al. The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib. Leukemia 2006;20: 658-663.
4. Bixby D, Talpaz M. Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia. Leukemia 2011;25: 7-22.
5. Ernst T, La Rosée P, Müller MC, et al. BCR-ABL mutations in chronic myeloid leukemia. Hematol Oncol Clin North Am 2011;25: 997-1008.
6. Branford S, Hughes T. Detection of BCR-ABL mutations and resistance to imatinib mesylate. Methods Mol Med 2006;125: 93-106.
7. BengióRM, Riva ME, Moiraghi B, et al. Clinical outcome of chronic myeloid leukemia imatinib-resistant patients: do BCR-ABL kinase domain mutations afect patient survival? First multicenter Argentinean study. Leuk Lymphoma 2011;52: 1720-1726.
8. Jabbour E, Kantarjian H, Cortes J. Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one? Semin Hematol 2010;47: 344-353.
9. Wittwer CT, Reed GH, Gundry CN, et al. High resolution genotyping by amplicon melting analysis using LC Green. Clin Chem 2003;9: 853-860.
10. Yin CC, Cortes J, Galbincea J, et al. Rapid clonal shifts in response to kinase inhibitor therapy in chronic myelogenous leukemia are identifed by quantitation mutation assays. Cancer Sci 2010;101: 2005-2010.
11. Gruber FX, Ernst T, Kiselev Y, et al. Detection of drug-resistant clones in chronic myelogenous leukemia patients during dasatinib and nilotinib treatment. Clin Chem 2010;56: 469-473.
12. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia recommendations from an expert panel on behalf of the Erropean Leukemia Net. Blood 2006;108: 1809-1817.
13. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European Leukemia Net. J Clin Oncol 2009;27: 6041-6051.
14. Hughes TP, Kaeda J, Branford S, et al.: International Randomised Study of Interferon versus STI571 (IRIS) Study Group. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003;349: 1423-1432.
15. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplifcation. Science 2001;293: 876-880.
16. Branford S, Rudzki Z, Walsh S, et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002;99: 3472-3475.
17. Mathisen M, Kantarjian H, Cortes J, et al. Mutant BCR-ABL clones in chronic myeloid leukemia. Haematologica 2011;96: 347-349.
18. Branford S, Rudzki Z, Wals S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompained by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003;102: 276-283.
19. Clayton SJ, Scott FM, Walker J, et al. K-ras point mutation detection in lung cancer: comparison of two approaches to somatic mutation detection using ARMS allele-specifc amplifcacion. Clin Chem 2000;46: 1929-1938.
20. Doi Y, Sasaki D, Terada CH, et al. High-resolution melting analysis for a reliable and two-step scanning of mutations in the tyrosine kinase domain of the chimerical bcr-abl gene. Int J Hematol 2009;90: 37-43.
21. Poláková KM, Lopotová T, Klamová H, et al. High-resolution melt curve analysis: initial screening for mutations in BCR-ABL kinase domain. Leuk Res 2008;32: 1236-1243.
22. Hughes T, Deininger M, Hochhaus A. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodogy for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006;108: 28-37.
23. Branford S, Rudzki Z, Parkinson I, et al. Real time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood 2004;104: 2926-2932.
24. Olsson-Stromberg U, Hermansson M, Lundán T, et al. Molecular monitoring and mutation analysis of patients with advanced phse CML and Ph+ ALL receiving dasatinib. Eur J Haematol 2010;85: 399-404.
25. Wang I, Knight K, Lucas C, et al. The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL mutations in imatinib treated patients with chronic myeloid leukemia. Haematologica 2006;91: 235-239.
26. Härtel N, Klag T, Hochhaus A, et al. Overexpression of the IL3/IL5/GM-CSFRB as potential mechanism leading to survival factor activation in response to ABL inhibitors treatment. Haematologica 2008;93(Suppl. 1): Abstract 382.
27. Hanfstein B, Muller MC, Kreil S, et al. Dynamics of mutant BCR-ABL positive clones after cessation of tyrosine kinase inhibitor therapy. Haematologica 2011;96: 360-366.